CFO Jeffrey B. McGroarty departs Annovis; severance includes 3-mo salary, 2-year option extension, stock sale lock-up

Annovis Bio, Inc.

McGroarty's last day as CFO and employee was September 9, 2022; Henry Hagopian III named CFO earlier.
Severance includes 3 months base salary, health coverage, and 2-year option exercise extension.
McGroarty agrees to 24-month lock-up on stock sales; allows up to 100K shares per 6-month period with volume cap.
Agreement includes non-solicitation, cooperation, non-disparagement, and general release of claims.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jeffrey B. McGroarty

Chief Financial Officer

ANVS · Annovis Bio, Inc.

Effective: 2022-09-09
Successor: Henry Hagopian III
Filed: September 12, 2022, 7:59 PM ET

Jeffrey B. McGroarty, formerly Chief Financial Officer, Treasurer and Corporate Secretary of the Company, was stepping down from his role to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey B. McGroarty departed as Chief Financial Officer at Annovis Bio, Inc..

Action: stepped down
Role: Chief Financial Officer

Exact text from the filing

Jeffrey B. McGroarty, formerly Chief Financial Officer, Treasurer and Corporate Secretary of the Company, was stepping down from his role to pursue other opportunities.

View on SEC.gov

Annovis Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-099298

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.